Former Biomet CEO Joins Minimus Spine Board of Directors

Minimus Spine, manufacturer of the Triojection system for herniated spinal discs, has appointed Jeffrey R. Binder to its Board of Directors. Binder was CEO of Biomet from 2007 until it was acquired for approximately $14 billion by Zimmer Holdings Inc. in 2015.

Binder is currently president and CEO of Immucor.
 
Prior to his time at Biomet, Binder was president of Abbott Diagnostics from 2006 to 2007 and CEO of Spinal Concepts from 2000 until it was acquired by Abbott Laboratories in 2003 and became Abbott Spine. Prior to Spinal Concepts, Binder was president of Depuy Orthopedics and has spent most of his career in orthopedics and spine.

David Hooper, Ph.D., Minimus Spine’s president and CEO said, “Jeff brings a wealth of intellect and experience to Minimus. He has successfully orchestrated several significant transactions in spine and orthopedics and is unquestionably a blue-chip addition as we strengthen the team around Triojection. Our management team and board worked together at Spinal Concepts. While that was a great result, the market need has expanded far beyond spinal hardware. We share the vision that Minimus is part of the future of spine and we expect continued success as we plan the initial commercial launch of Triojection in Europe this summer.”
 
“I am very pleased to join the board of this exciting and young company,” Binder said. “Clinicians and patients are searching for solutions that address spinal disorders and reduce pain with less invasive approaches. I’m looking forward to working again with David and fellow director Wes Johnson, who were both so instrumental to our success at Spinal Concepts.”
 
Minimus Spine is dedicated to the non-surgical treatment of disc herniation patients using an intradiscal injection of ozone gas to the herniated disc. Minimus Spine is the manufacturer of the Triojection System, which involves a sterile, single-use, syringe cartridge that is processed in the operating room using the Triojection console. Triojection provides the physician with confidence in both the sterility of the procedure and the concentration of ozone delivered to the patient.